Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Interest & Investment Income (2022 - 2025)

Historic Interest & Investment Income for Foghorn Therapeutics (FHTX) over the last 4 years, with Q3 2025 value amounting to $2.0 million.

  • Foghorn Therapeutics' Interest & Investment Income fell 4185.98% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 1164.52%. This contributed to the annual value of $11.9 million for FY2024, which is 942.53% up from last year.
  • Foghorn Therapeutics' Interest & Investment Income amounted to $2.0 million in Q3 2025, which was down 4185.98% from $2.3 million recorded in Q2 2025.
  • Foghorn Therapeutics' Interest & Investment Income's 5-year high stood at $3.5 million during Q3 2024, with a 5-year trough of $235000.0 in Q1 2022.
  • Over the past 4 years, Foghorn Therapeutics' median Interest & Investment Income value was $2.7 million (recorded in 2023), while the average stood at $2.4 million.
  • In the last 5 years, Foghorn Therapeutics' Interest & Investment Income skyrocketed by 103574.47% in 2023 and then plummeted by 4185.98% in 2025.
  • Over the past 4 years, Foghorn Therapeutics' Interest & Investment Income (Quarter) stood at $2.4 million in 2022, then grew by 11.95% to $2.7 million in 2023, then grew by 16.39% to $3.1 million in 2024, then tumbled by 34.37% to $2.0 million in 2025.
  • Its Interest & Investment Income stands at $2.0 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.7 million for Q1 2025.